Concord Medical Signs Framework Agreement for Cancer Specialty Hospital in Beijing
Concord Medical Services (NYSE: CCM) today announced that it has signed a framework agreement with Beijing International Medical Center ("BIMC") to establish a cancer specialty hospital.
Under the agreement, the hospital will be wholly owned by Concord Medical and provide comprehensive cancer therapies, including surgery, chemotherapy, radiotherapy and gene therapy, to high-end cancer patients. Concord Medical will provide management support, treatment, technology and research to the hospital, including protocols and clinical practice guidelines, by collaborating with top-notch cancer institutions around the world. Concord Medical plans to begin designing of the hospital and other early-stage works soon.
Dr. Jianyu Yang, Chairman and CEO of Concord Medical, said, "We are excited to participate in the BIMC project, which is expected to develop into a premiere healthcare zone. We will leverage the resources of our international partners, our 15-year experience in cancer radiotherapy and our capital market strength to build a premium private hospital focused on cancer treatment and diagnosis. This agreement marks a milestone in Concord Medical's initiatives to become